{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-008748","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.438712+00:00","generated_at":"2026-05-22T14:23:20.828410+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MIRA Pharma reports no brain toxicity in FDA-required Ketamir-2 study","bullets":["Ketamir-2 showed no mortality, adverse signs, or brain lesions in rats at high doses.","Positive control MK-801 caused vacuolation and neuronal necrosis (Olney lesions).","Results to be submitted to FDA as part of ongoing regulatory communications.","Study supports Ketamir-2's safety profile versus ketamine-linked neurotoxicity."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-008748","json":"https://secwatch.observer/filing/0001641172-25-008748.json","markdown":"https://secwatch.observer/filing/0001641172-25-008748.md","text":"https://secwatch.observer/filing/0001641172-25-008748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225008748/0001641172-25-008748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225008748/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T14:23:20.828410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}